
Radiant Biotherapeutics Secures $35 Million in Series A Funding to Propel Multabody™ Platform
Radiant Biotherapeutics, a cutting-edge biotechnology firm specializing in advanced antibody therapies, has announced the successful closure of a $35 million Series A financing round. This significant investment, spearheaded by the Bill & Melinda Gates Foundation and Amplitude Ventures, aims to further develop Radiant’s innovative Multabody™ platform, which is poised to revolutionize therapeutic approaches across various…